7Baggers
Quarterly
Annual
    Unit: USD2026-09-30 2025-12-31 2025-09-30 2025-06-30 2025-03-31 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2018-03-31 2017-12-31 2017-09-30 2017-06-30 2017-03-31 2016-12-31 2016-09-30 2016-06-30 2015-06-30 2015-03-31 2014-12-31 2014-09-30 2014-06-30 2014-03-31 2013-12-31 2013-09-30 2013-06-30 2013-03-31 2012-12-31 2012-09-30 2012-06-30 2012-03-31 2011-12-31 2011-09-30 2011-06-30 2011-03-31 2010-12-31 2010-09-30 2010-06-30 2010-03-31 2009-12-31 2009-09-30 2009-06-30 2009-03-31 2008-12-31 2008-09-30 2008-06-30 2008-03-31 2007-12-31 2007-09-30 2007-06-30 2007-03-31 2006-12-31 2006-09-30 2006-06-30 2006-03-31 2005-12-31 2005-09-30 
      
    		                                                                                
      cash flows from operating activities:
    		                                                                                
      net earnings
    		454,000,000   243,000,000   6,000,000    111,000,000               280,000,000 594,000,000 195,000,000 0 1,053,000,000 117,000,000 -1,166,000,000 791,000,000 324,000,000 310,000,000 278,000,000 306,000,000 326,000,000 384,000,000 335,000,000 295,000,000 365,000,000 289,000,000 266,000,000 234,000,000 315,000,000 278,000,000 339,000,000 -586,000,000 345,000,000 304,000,000 271,000,000 236,800,000 333,400,000 262,000,000 236,800,000 202,700,000 246,100,000   223,500,000 222,400,000   273,200,000 312,800,000 316,500,000 249,100,000 318,000,000 356,100,000 324,700,000 301,800,000 902,200,000 18,900,000 739,300,000 270,700,000 321,000,000    
      adjustments to reconcile net earnings to net cash provided by/(used in) operating activities:
    		                                                                                
      depreciation and amortization
    		233,000,000 192,000,000 182,000,000 209,000,000 234,000,000 175,000,000 172,000,000 186,000,000 183,000,000 170,000,000 171,000,000 176,000,000 184,000,000 164,000,000 168,000,000 179,000,000 109,000,000 199,000,000 205,000,000 180,000,000 139,000,000 230,000,000 234,000,000 225,000,000 190,000,000 253,000,000 245,000,000 241,000,000 239,000,000 291,000,000 229,000,000 253,000,000 440,000,000 166,000,000 173,000,000 192,000,000 219,000,000 169,000,000 137,000,000 176,000,000 115,000,000 116,000,000 112,000,000 108,000,000 115,000,000 110,000,000 117,000,000 117,000,000 122,000,000 99,000,000 88,000,000 88,000,000 85,700,000 83,500,000 77,600,000 78,200,000 74,100,000 97,500,000 73,200,000 68,500,000 60,000,000 68,600,000 59,500,000 66,300,000 106,000,000 92,900,000 99,500,000 101,000,000 96,400,000 93,000,000 97,000,000 94,900,000 85,000,000 81,700,000 51,200,000 104,200,000 101,600,000 89,800,000 98,200,000 103,100,000 
      impairments and loss on sale of other investments
    		5,000,000   1,000,000            21,000,000            1,000,000 -4,000,000 0 6,000,000 0 3,000,000                                                
      impairments and (gain)/loss on disposal of assets
    		2,000,000 3,000,000 -1,000,000 33,000,000 -553,000,000 1,000,000 537,000,000 12,000,000 -241,000,000 710,000,000 153,000,000 367,000,000 -410,000,000 1,295,000,000 -2,000,000 286,000,000 1,755,000,000 0 9,000,000 1,000,000 70,000,000 7,000,000 1,000,000  510,000,000 8,000,000 -511,000,000             4,000,000 0 -1,000,000                                       
      share-based compensation
    		93,000,000 30,000,000 30,000,000 153,000,000 34,000,000 28,000,000 29,000,000 33,000,000 40,000,000 25,000,000 23,000,000 27,000,000 27,000,000 18,000,000 24,000,000 16,000,000 14,000,000 23,000,000 28,000,000 5,000,000 43,000,000 21,000,000 20,000,000 22,000,000 27,000,000 22,000,000 19,000,000 18,000,000 24,000,000 23,000,000 17,000,000 21,000,000 17,000,000 24,000,000 23,000,000 23,000,000 17,000,000 26,000,000 30,000,000 29,000,000 30,000,000 27,000,000 28,000,000 25,000,000 24,000,000 24,000,000 24,000,000 24,000,000 25,000,000 22,000,000 22,000,000 24,000,000 21,900,000 21,600,000 21,700,000 19,800,000 19,100,000 18,000,000 21,000,000 21,400,000                     
      benefit from bad debts
    		13,000,000 12,000,000 16,000,000 12,000,000 -2,000,000 14,000,000 29,000,000 -23,000,000 0 30,000,000 29,000,000 20,000,000 54,000,000 13,000,000 12,000,000 22,000,000 11,000,000 19,000,000 16,000,000 16,000,000 2,000,000 18,000,000 29,000,000 20,000,000 46,000,000 19,000,000 21,000,000 29,000,000 10,000,000 24,000,000 25,000,000 35,000,000 47,000,000 22,000,000 7,000,000 17,000,000 11,000,000 18,000,000 17,000,000 22,000,000 10,000,000 16,000,000 14,000,000 12,000,000 11,000,000 2,000,000 17,000,000 12,000,000 13,000,000 9,000,000 8,000,000 1,000,000 15,300,000 5,000,000 800,000 900,000 5,000,000 14,400,000 5,100,000 2,700,000 -6,400,000 11,800,000 9,100,000 12,300,000 8,500,000 26,800,000 14,200,000 12,600,000 3,800,000 11,900,000 5,400,000 5,000,000 7,000,000 9,200,000 2,700,000 5,100,000 12,500,000 -200,000 7,400,000 9,000,000 
      change in operating assets and liabilities, net of effects from acquisitions and divestitures:
    		                                                                                
      (increase)/decrease in trade receivables
    		-539,000,000      50,000,000           -111,000,000 -388,000,000   -108,000,000 229,000,000    -302,000,000                                                 121,000,000  -733,300,000   
      increase in inventories
    		-736,000,000 -1,289,000,000 -678,000,000  1,327,000,000 -1,479,000,000 -1,057,000,000  272,000,000 -1,379,000,000 -264,000,000 672,000,000 -651,000,000 -232,000,000 -129,000,000 -149,000,000 334,000,000   -261,000,000 -332,000,000   -401,000,000 745,000,000   -206,000,000 650,000,000 -614,000,000 -381,000,000 -346,000,000 429,000,000 -996,000,000 -298,000,000 337,000,000 555,000,000            -27,000,000 193,000,000 -329,000,000 -207,000,000  682,700,000 -1,391,700,000 -160,900,000  552,200,000 -868,500,000 -731,800,000   -1,099,100,000 -28,100,000                -2,900,000 
      increase/(decrease) in accounts payable
    		2,147,000,000 924,000,000 -1,394,000,000        1,234,000,000    -292,000,000   1,548,000,000 313,000,000   1,735,000,000 -1,812,000,000    559,000,000            425,000,000  291,000,000 219,000,000   1,196,000,000 -304,000,000 764,000,000 -1,852,000,000                    982,600,000        -131,100,000     
      other accrued liabilities and operating items
    		-699,000,000 -133,000,000 -508,000,000 -72,000,000 500,000,000 -86,000,000 -948,000,000 437,000,000 194,000,000 -138,000,000 -926,000,000 -122,000,000 997,000,000 -1,347,000,000 -495,000,000 499,000,000 -710,000,000 -81,000,000 585,000,000 -567,000,000 -4,109,000,000 -83,000,000 5,211,000,000 1,125,000,000 5,638,000,000 -129,000,000 -84,000,000 -116,000,000 1,199,000,000 -1,119,000,000 229,000,000 714,000,000 193,000,000 -442,000,000 -87,000,000 -193,000,000 -155,000,000 29,000,000 -201,000,000 -121,000,000 -16,000,000 56,000,000 209,000,000 -96,000,000 -139,000,000 201,000,000 5,000,000 -183,000,000 -447,000,000 263,000,000 -93,000,000 -4,000,000 -270,900,000 187,100,000 -32,500,000 -12,700,000 -185,600,000 221,500,000 -197,500,000 -125,400,000   -159,400,000 -99,600,000 74,600,000 264,500,000 -282,800,000 -49,800,000 -89,400,000   56,900,000 -667,500,000 573,600,000 -47,400,000 177,100,000 -500,000 37,000,000 -76,300,000 137,800,000 
      net cash provided by/(used in) operating activities
    		973,000,000 -400,000,000 -1,647,000,000        23,000,000    -646,000,000    270,000,000    -653,000,000            104,000,000    -52,000,000                         406,000,000                 
      cash flows from investing activities:
    		                                                                                
      acquisition of subsidiaries, net of cash acquired
    		-41,000,000   -1,395,000,000    2,000,000    0        0        -44,000,000 6,103,000,000 -2,000,000 -6,139,000,000 0 -6,131,000,000 -2,000,000 -9,000,000 -19,000,000 3,171,000,000 -1,885,000,000 -1,399,000,000 -231,000,000 -184,000,000 -233,000,000 -25,000,000 -61,000,000 -351,000,000 -118,000,000 -25,000,000 -25,000,000 -20,000,000 -2,093,000,000 -26,000,000 -100,000,000 -31,400,000 -135,300,000 0 -7,300,000   -1,735,100,000 -559,900,000                     
      additions to property and equipment
    		-108,000,000 -99,000,000 -90,000,000 -232,000,000 -109,000,000 -114,000,000 -92,000,000 -193,000,000 -163,000,000 -85,000,000 -70,000,000 -217,000,000 -123,000,000 -74,000,000 -67,000,000 -164,000,000 -49,000,000 -96,000,000 -78,000,000 -126,000,000 -125,000,000 -77,000,000 -72,000,000 -136,000,000 -123,000,000 -58,000,000 -58,000,000 -136,000,000 -24,000,000 -101,000,000 -67,000,000 -138,000,000 -33,000,000 -113,000,000 -100,000,000 -94,000,000 -118,000,000 -92,000,000 -83,000,000 -181,000,000 -161,000,000 -56,000,000 -47,000,000 -36,000,000 -111,000,000 -48,000,000 -64,000,000 -26,000,000 -92,000,000 -41,000,000 -36,000,000 -26,000,000 -104,000,000 -57,700,000 -57,000,000 -44,300,000 -105,300,000 -59,900,000 -64,100,000 -62,000,000   -42,900,000 -37,000,000 -270,300,000 -80,900,000   -124,500,000 -79,500,000 -80,600,000 -91,500,000 -114,300,000 -89,100,000 -68,700,000 -85,300,000 -112,700,000 -112,300,000 -142,200,000 -76,000,000 
      other investing items
    		7,000,000                                                                                
      net cash from investing activities
    		-142,000,000 -976,000,000 -88,000,000 -1,631,000,000 -3,794,000,000 -105,000,000 -63,000,000           -97,000,000 -94,000,000           -105,000,000 -6,144,000,000 -140,000,000 -5,231,000,000 -127,000,000 -110,000,000 24,000,000 3,042,000,000 -1,993,000,000 -1,478,000,000 -399,000,000 -463,000,000 -286,000,000 -19,000,000 -81,000,000 -564,000,000 -146,000,000 -89,000,000 -51,000,000 -118,000,000 -2,140,000,000 -14,000,000 -103,000,000  -182,000,000          -74,100,000  -92,900,000 -81,400,000 -94,700,000  -76,400,000 -26,800,000 -45,200,000  -31,800,000 -154,400,000 -83,900,000 -361,800,000 -223,300,000 -429,900,000 -172,200,000 
      cash flows from financing activities:
    		                                                                                
      proceeds from long-term obligations, net of issuance costs
    		989,000,000   800,000,000    0                     -2,000,000   0         1,490,000,000 0       0    496,000,000 0   0 0   0    -24,400,000 3,100,000 13,200,000 8,500,000   900,000 100,000 601,700,000 0 840,500,000 11,200,000 84,100,000 2,500,000 502,500,000 5,900,000 
      reduction of long-term obligations
    		-512,000,000 -414,000,000 -9,000,000 -11,000,000 -419,000,000 -8,000,000 -7,000,000 -760,000,000 -10,000,000 -6,000,000 -7,000,000 -8,000,000 21,000,000 -5,000,000 -587,000,000 -288,000,000 -548,000,000 -9,000,000 -40,000,000 -517,000,000 740,000,000 -719,000,000 -74,000,000 -511,000,000 -886,000,000 -1,000,000 -1,000,000 -1,099,000,000 400,000,000 -1,000,000 -402,000,000 -551,000,000 -343,000,000 -59,000,000 -1,000,000 -250,000,000 -56,000,000 0 -4,000,000 -1,000,000 0 -1,000,000   -1,000,000 0   -299,000,000 0 -2,000,000 -4,000,000 -206,500,000 -43,500,000 -500,000 -500,000 -500,000 -218,700,000 -9,000,000 -400,000   -350,500,000 -1,134,400,000 5,500,000 -3,000,000 -154,500,000 -152,600,000 -5,600,000 -1,800,000 -1,100,000 -13,000,000 -51,100,000 -43,700,000 -659,700,000 -29,500,000 -45,400,000 -160,900,000 -96,100,000 -3,700,000 
      purchases/(payments) of noncontrolling interests
    		-3,000,000                                                                                
      net tax withholding from share-based compensation
    		-80,000,000  -28,000,000                                                                              
      dividends on common shares
    		-129,000,000 -122,000,000 -128,000,000 -120,000,000 -119,000,000 -124,000,000 -131,000,000 -122,000,000 -106,000,000 -129,000,000 -142,000,000 -126,000,000 -110,000,000 -140,000,000 -149,000,000 -134,000,000 -136,000,000 -143,000,000 -146,000,000 -141,000,000 -145,000,000 -141,000,000 -146,000,000 -141,000,000 -135,000,000 -143,000,000 -150,000,000 -142,000,000 -139,000,000 -146,000,000 -150,000,000 -145,000,000 -143,000,000 -144,000,000 -149,000,000 -142,000,000 -176,000,000 -128,000,000 -131,000,000 -126,000,000 -114,000,000 -113,000,000 -114,000,000 -119,000,000 -103,000,000 -104,000,000 -103,000,000 -105,000,000 -95,000,000 -93,000,000 -81,000,000 -84,000,000 -74,100,000 -74,300,000 -74,400,000 -77,200,000 -68,300,000 -67,900,000 -67,700,000 -70,300,000   -63,000,000 -64,200,000 -50,300,000 -50,100,000 -50,200,000 -49,800,000 -42,700,000 -42,700,000 -43,400,000 -44,300,000 -34,900,000 -36,100,000 -36,400,000 -37,000,000 -25,200,000 -25,400,000 -25,700,000 -25,500,000 
      purchase of treasury shares
    		-375,000,000 -15,000,000 -375,000,000 0 -15,000,000 -250,000,000 -500,000,000 0 500,000,000 -250,000,000 -1,000,000,000 -500,000,000 -700,000,000 -300,000,000 -500,000,000 0    0 150,000,000 0 -350,000,000 0 250,000,000 0 -600,000,000 0 -450,000,000 0 -150,000,000 -100,000,000 150,000,000 -350,000,000 -250,000,000 0    -351,000,000 -350,000,000 0 -326,000,000 -360,000,000 -284,000,000 -339,000,000 0 -50,000,000 -250,000,000 0 0 -200,000,000 -150,000,000 0 0 -300,000,000 0 0 0 -269,800,000            -674,700,000 -1,636,800,000 -1,279,900,000 -300,000,000 -445,300,000 -526,900,000 -560,100,000   
      net cash from financing activities
    		-110,000,000  -540,000,000  2,303,000,000 -353,000,000 -666,000,000   -362,000,000 -1,163,000,000 -592,000,000 -751,000,000 -444,000,000 -1,264,000,000 -415,000,000 -1,704,000,000 -146,000,000 -198,000,000 -649,000,000 92,000,000 -175,000,000 -585,000,000 -528,000,000 -764,000,000 -144,000,000 -764,000,000  -220,000,000 -86,000,000 -744,000,000  -581,000,000 -536,000,000 -350,000,000  -792,000,000 -110,000,000 -112,000,000   -70,000,000 -522,000,000 -376,000,000   40,000,000 -48,000,000   -41,000,000 -299,000,000 81,700,000   -381,300,000 -52,100,000        -72,300,000 -134,600,000 -89,800,000 -171,500,000 98,000,000 -466,200,000 -52,200,000 -382,800,000 -1,178,300,000    -514,300,000    
      effect of exchange rates changes on cash and equivalents
    		-2,000,000  9,000,000                 3,000,000 13,000,000   -12,000,000 3,000,000 -6,000,000 2,000,000 3,000,000 -9,000,000 -2,000,000 9,000,000 -13,000,000 27,000,000 -11,000,000 1,000,000 3,000,000                                             
      net increase/(decrease) in cash and equivalents
    		719,000,000                -2,017,000,000    1,600,000,000 447,000,000 -1,319,000,000 442,000,000 -621,000,000 137,000,000 282,000,000 -907,000,000            -242,000,000    -396,000,000         -136,100,000   81,300,000 -32,500,000 613,800,000 -1,364,200,000 -43,100,000   162,000,000 363,200,000     -237,700,000            
      cash and equivalents at beginning of period
    		3,874,000,000 0 5,133,000,000 0 1,090,000,000 0 4,043,000,000 33,000,000 -674,000,000 0 4,717,000,000 0 1,310,000,000 0 3,407,000,000 0 636,000,000 0 2,771,000,000 0 240,000,000 0 2,531,000,000 0 768,000,000 0 1,763,000,000 0 -5,116,000,000 0 6,879,000,000 0 4,523,000,000 0 2,356,000,000 0 -2,260,000,000 0 4,616,000,000 0 0 0 0 2,865,000,000 0 0 0 1,901,000,000 0 0 0 2,274,000,000  0 0 1,929,300,000  0 0 2,755,300,000  0 0 1,221,600,000  0 0 1,291,300,000  0 0 1,308,800,000  1,000,000 -134,600,000 1,320,900,000  -1,200,000 0 1,401,200,000 
      cash and equivalents at end of period
    		4,593,000,000 943,000,000 2,867,000,000 548,000,000 -1,265,000,000 737,000,000 3,854,000,000 1,415,000,000 64,000,000 162,000,000 3,492,000,000 53,000,000 829,000,000 698,000,000 2,463,000,000 2,361,000,000 -1,381,000,000 991,000,000 2,746,000,000 -92,000,000 1,840,000,000 447,000,000 1,212,000,000 442,000,000 147,000,000 137,000,000 2,045,000,000 -907,000,000 2,189,000,000 68,000,000 1,181,000,000 -412,000,000 294,000,000 -120,000,000 2,001,000,000 5,511,000,000 -956,000,000 -650,000,000 2,974,000,000 -242,000,000 1,433,000,000 302,000,000 412,000,000 2,469,000,000 -176,000,000 300,000,000 -12,000,000 2,753,000,000 -404,000,000 50,000,000 -185,000,000 2,440,000,000  612,700,000 -212,900,000 2,010,600,000  613,800,000 -1,364,200,000 2,712,200,000  892,000,000 162,000,000 1,584,800,000  593,400,000 100,400,000 672,200,000  344,600,000 -105,200,000 1,289,600,000  -136,800,000 -606,300,000 1,609,600,000  -510,500,000 247,000,000 1,976,900,000 
      adjustments to reconcile net earnings to net cash from operating activities:
    		                                                                                
      increase in trade receivables
    		   -466,000,000 120,000,000   -734,000,000 657,000,000 -411,000,000 -508,000,000 -437,000,000 -181,000,000 -115,000,000 -214,000,000          -462,000,000   -595,000,000 461,000,000 -258,000,000 -359,000,000 -239,000,000 -486,000,000 160,000,000 -306,000,000 -558,000,000 286,000,000 -45,000,000 -348,000,000             -71,000,000    -69,300,000    -272,300,000    -716,100,000 220,900,000 -716,200,000 628,900,000 -782,400,000 -17,900,000 -144,200,000   36,500,000 -227,500,000       
      proceeds from divestitures, net of cash sold
    		 0 2,000,000  -7,000,000   0                                                                         
      proceeds from disposal of property and equipment
    		    1,000,000 1,000,000 1,000,000 2,000,000 8,000,000 0 2,000,000 10,000,000                   1,000,000                                                  
      purchases of investments
    		    -4,000,000 -1,000,000 -1,000,000  2,000,000 -2,000,000 -3,000,000  -2,000,000 -2,000,000 -2,000,000                                                                  
      proceeds from investments
    		    6,000,000 0 1,000,000 0 0 0 1,000,000  -21,000,000 18,000,000 4,000,000  23,000,000 3,000,000 1,000,000                                                              
      proceeds from net investment hedge terminations
    		   0 -26,000,000 0 28,000,000 6,000,000    0    0                                                                 
      proceeds from short-term investment in time deposit
    		   0                                                                             
      net tax proceeds/(withholding) from share-based compensation
    		   -1,000,000                                                                             
      net cash provided by/(used in) financing activities
    		                                            -328,000,000    -586,000,000          429,500,000 -344,200,000    31,300,000            -345,700,000   16,000,000 23,900,000 
      effect of exchange rate changes on cash and equivalents
    		    0 6,000,000 -5,000,000  -6,000,000 14,000,000 -15,000,000  10,000,000 -6,000,000 -5,000,000    -3,000,000    -8,000,000                                                          
      25
    		                                                                                
      net earnings/
    		  417,000,000         -66,000,000   272,000,000 137,000,000 -1,446,000,000   115,000,000 5,198,000,000 220,000,000 -4,921,000,000 657,000,000                                    294,800,000    -38,200,000                 
      adjustments to reconcile net earnings/(loss) to net cash provided by/(used in) operating activities:
    		                                                                                
      impairments and (gain)/loss on sale of investments
    		  1,000,000                        2,000,000                                                      
      decrease in trade receivables
    		  288,000,000                                           53,000,000                                   
      net decrease in cash and equivalents
    		  -2,266,000,000    -189,000,000  738,000,000 162,000,000 -1,225,000,000    -944,000,000    -25,000,000           68,000,000 -5,698,000,000  -4,229,000,000 -120,000,000 -355,000,000    -1,642,000,000                            100,400,000 -619,100,000             
      benefit from/(benefit from) deferred income taxes
    		                                                                                
      (increase)/decrease in inventories
    		                  -245,000,000    356,000,000    -178,000,000                                         -873,600,000             
      increase in accounts payable
    		   1,778,000,000 -3,492,000,000 2,719,000,000 1,727,000,000 -452,000,000 -678,000,000   245,000,000 1,414,000,000            -493,000,000   1,018,000,000 -1,261,000,000 811,000,000 1,296,000,000 939,000,000 72,000,000 1,284,000,000 279,000,000 339,000,000 -2,206,000,000            212,000,000 183,000,000 -433,000,000 464,000,000 -893,200,000 94,600,000 707,800,000 409,800,000  223,600,000 729,700,000 1,033,100,000  223,500,000 496,100,000 1,003,100,000         -268,700,000 417,000,000   46,100,000 965,800,000 33,700,000 470,500,000 
      net cash from operating activities
    		   1,527,000,000 -864,000,000 1,189,000,000 545,000,000 2,077,000,000 1,065,000,000   858,000,000 1,432,000,000   2,992,000,000 -1,357,000,000   665,000,000 1,720,000,000   240,000,000 984,000,000 371,000,000 365,000,000 506,000,000 756,000,000 279,000,000 1,181,000,000 554,000,000 1,556,000,000   724,000,000 -951,000,000   641,000,000 868,000,000 658,000,000 953,000,000 61,000,000 716,000,000 820,000,000 37,000,000 951,000,000 300,000,000 989,000,000 -130,000,000 568,000,000 -106,900,000 893,200,000 -114,500,000 504,200,000 119,800,000 914,000,000 143,800,000 217,000,000 324,200,000 879,300,000   827,700,000    242,300,000 887,200,000 -26,200,000 408,800,000 -186,700,000 770,400,000 -78,900,000 718,300,000 483,600,000 271,800,000 660,900,000 724,000,000 
      capex
    		   -232,000,000 -109,000,000 -114,000,000 -92,000,000 -193,000,000 -163,000,000   -217,000,000 -123,000,000   -164,000,000 -49,000,000   -126,000,000 -125,000,000   -136,000,000 -123,000,000 -58,000,000 -58,000,000 -136,000,000 -24,000,000 -101,000,000 -67,000,000 -138,000,000 -33,000,000   -94,000,000 -118,000,000   -181,000,000 -161,000,000 -56,000,000 -47,000,000 -36,000,000 -111,000,000 -48,000,000 -64,000,000 -26,000,000 -92,000,000 -41,000,000 -36,000,000 -26,000,000 -104,000,000 -57,700,000 -57,000,000 -44,300,000 -105,300,000 -59,900,000 -64,100,000 -62,000,000 0 0   -270,300,000    -124,500,000 -79,500,000 -80,600,000 -91,500,000 -114,300,000 -89,100,000 -68,700,000 -85,300,000 -112,700,000 -112,300,000 -142,200,000 -76,000,000 
      free cash flows
    		   1,295,000,000 -973,000,000 1,075,000,000 453,000,000 1,884,000,000 902,000,000   641,000,000 1,309,000,000   2,828,000,000 -1,406,000,000   539,000,000 1,595,000,000   104,000,000 861,000,000 313,000,000 307,000,000 370,000,000 732,000,000 178,000,000 1,114,000,000 416,000,000 1,523,000,000   630,000,000 -1,069,000,000   460,000,000 707,000,000 602,000,000 906,000,000 25,000,000 605,000,000 772,000,000 -27,000,000 925,000,000 208,000,000 948,000,000 -166,000,000 542,000,000 -210,900,000 835,500,000 -171,500,000 459,900,000 14,500,000 854,100,000 79,700,000 155,000,000 324,200,000 879,300,000   557,400,000    117,800,000 807,700,000 -106,800,000 317,300,000 -301,000,000 681,300,000 -147,600,000 633,000,000 370,900,000 159,500,000 518,700,000 648,000,000 
      purchase of short-term time deposits
    		                                                                                
      purchases and payments of noncontrolling interests
    		                                                                                
      supplemental information:
    		                                                                                
      cash payments for interest
    		                                                                                
      net cash payments for income taxes
    		                                                                                
      54
    		                                                                                
      adjustments to reconcile net earnings/(loss) to net cash from operating activities:
    		                                                                                
      net tax proceeds from share-based compensation
    		                                                                                
      27
    		                                                                                
      net tax withholdings from share-based compensation
    		      -28,000,000    -14,000,000   1,000,000 -28,000,000  -20,000,000 6,000,000 -12,000,000  10,000,000          -18,000,000    -9,000,000                                              
      gain on sale of equity interest in navihealth
    		                                                                                
      loss on early extinguishment of debt
    		             0 10,000,000 0 9,000,000   13,000,000                                                             
      purchase of investments
    		                 -1,000,000 -17,000,000  -12,000,000                                                            
      purchase of short-term investment in time deposit
    		                                                                                
      net cash provided by/(used in) investing activities
    		         -87,000,000 -70,000,000 -206,000,000 -1,063,000,000 -47,000,000 862,000,000 -204,000,000      -78,000,000 -73,000,000 742,000,000 -844,000,000 -84,000,000 679,000,000 -173,000,000                            -41,600,000 -100,200,000 -74,400,000 -1,937,500,000 84,100,000 21,500,000 88,100,000                   
      purchase of noncontrolling interests
    		                             -103,000,000 -3,000,000 0                                                 
      cash reclassified from/(to) assets held for sale
    		                                                                                
      net cash payments/(refunds) for income taxes
    		                                                                                
      56
    		                                                                                
      purchases of short-term time deposits
    		                                                                                
      (gain)/loss on sale of equity interest in navihealth
    		               0                                                                 
      net tax proceeds/(withholdings) from share-based compensation
    		                      -13,000,000   0 -13,000,000                                                      
      cash and equivalents reclassified from assets held for sale
    		                                                                                
      30
    		                                                                                
      cash reclassified from assets held for sale
    		             0 109,000,000                                                                  
      purchase of other investments
    		                                                                                
      proceeds from sale of investments
    		                                                                                
      proceeds from interest rate swap terminations
    		                   0              0 14,000,000 0                                             
      proceeds from divestitures, net of cash transferred, and disposal of property and equipment
    		             11,000,000 927,000,000                                                                  
      26
    		                                                                                
      net change in short-term borrowings
    		                     683,000,000 -2,000,000 0      161,000,000 -6,000,000 0 -83,000,000 8,000,000 25,000,000 -22,000,000 -14,000,000 3,000,000 36,000,000 -8,000,000 -3,000,000 9,000,000 -58,000,000 40,000,000 49,000,000 -8,000,000 53,000,000 20,000,000 10,000,000 -28,000,000 27,000,000 -10,000,000 4,800,000 4,100,000 9,100,000 -5,000,000 4,900,000                        
      net increase in cash and equivalents
    		                                         302,000,000      852,000,000    166,000,000         116,500,000               288,700,000  -509,300,000 247,000,000 575,700,000 
      60
    		                                                                                
      cash and equivalents reclassified from/(to) assets held for sale
    		                                                                                
      31
    		                                                                                
      29
    		                                                                                
      net income
    		                  -253,000,000                                                              
      adjustments to reconcile net income to net cash provided by/(used in) operating activities:
    		                                                                                
      proceeds from divestitures, net of cash sold, and disposal of property and equipment
    		                       0 -738,000,000 0 740,000,000 14,000,000    0                                                 
      cash reclassified to assets held for sale
    		                                                                                
      cash payments for income taxes
    		                                                                                
      cash and equivalents reclassified to assets held for sale
    		                                                                                
      33
    		                                                                                
      loss on extinguishment of debt
    		                             1,000,000 1,000,000 0         0 0               0 0 0 0 0 0                   
      purchase of available-for-sale securities and other investments
    		                      -3,000,000   -6,000,000 -4,000,000 -7,000,000 -5,000,000 -3,000,000 -3,000,000 -2,000,000 118,000,000   -6,000,000 -100,000,000 -62,000,000 -26,000,000  -208,000,000 -27,000,000 -32,000,000 -75,000,000                                     
      proceeds from sale of available-for-sale securities and other investments
    		                      2,000,000   0 1,000,000 0 -62,000,000 1,000,000 64,000,000 0 -7,000,000 38,000,000 34,000,000 113,000,000 58,000,000 32,000,000 25,000,000 37,000,000 77,000,000 22,000,000 16,000,000 91,000,000                                     
      impairments and loss/(gain) on disposal of assets
    		                                                                                
      change in fair value of contingent consideration obligation
    		                               0      -13,000,000 -1,000,000 0             -17,800,000                            
      decrease/(increase) in trade receivables
    		                                        -152,000,000 -427,000,000 0 -291,000,000    1,395,000,000 135,000,000                               -274,700,000 
      proceeds from sale of investments and available-for-sale securities
    		                                                                                
      payment of contingent consideration obligation
    		                             -2,000,000 -15,000,000 -13,000,000    0 20,000,000 0 -23,000,000 -2,000,000 -4,000,000                                        
      53
    		                                                                                
      proceeds from return of investments
    		                                                                                
      impairments and (gain)/loss on sale of other investments
    		                                                                                
      proceeds from maturities of available-for-sale securities
    		                                 22,000,000 17,000,000 28,000,000 30,000,000   13,000,000  8,000,000                                       
      21
    		                                                                                
      excess tax benefits from share-based compensation
    		                                  30,000,000 -3,000,000    0                                         
      23
    		                                                                                
      impairments and loss on disposal of assets
    		                             67,000,000 1,000,000 1,355,000,000 50,000,000 9,000,000 3,000,000          5,000,000 1,000,000   832,000,000 21,000,000 5,000,000 1,000,000 1,600,000                            
      change in operating assets and liabilities, net of effects from acquisitions:
    		                                                                                
      proceeds from divestitures and disposal of property and equipment and held for sale assets
    		                                   2,000,000                                             
      47
    		                                                                                
      net purchase of noncontrolling interests
    		                                 -2,000,000 -10,000,000 0                                             
      tax proceeds from share-based compensation
    		                                     1,000,000 31,000,000   14,000,000 4,000,000 38,000,000                                     
      19
    		                                                                                
      purchase of available for sale securities and other investments
    		                                  -52,000,000                                              
      earnings from discontinued operations, net of tax
    		                                                                                
      earnings from continuing operations
    		                                        292,000,000 365,000,000 289,000,000 266,000,000 234,000,000 315,000,000 274,000,000 340,000,000 -586,000,000 346,000,000 303,000,000 272,000,000 236,100,000 332,500,000 264,300,000 237,100,000 207,400,000 249,500,000   193,800,000 224,800,000   260,700,000 313,400,000 318,900,000 249,800,000 321,600,000 366,000,000 325,100,000 303,200,000 237,700,000 -5,300,000 307,000,000 300,300,000  367,300,000 304,000,000 234,600,000 
      adjustments to reconcile earnings from continuing operations to net cash from operating activities:
    		                                                                                
      (gain)/loss on sale of other investments
    		                                                                                
      benefit from deferred income taxes
    		                                                                                
      45
    		                                                                                
      gain on sale of other investments
    		                                        0 0 0 -5,000,000                                     
      proceeds from divestitures and disposal of held for sale assets
    		                                        0 0                                       
      net proceeds/(tax withholdings) from share-based compensation
    		                                     14,000,000 -21,000,000                                          
      17
    		                                                                                
      decrease/(increase) in inventories
    		                                      -495,000,000  71,000,000    -208,000,000   1,098,000,000                                 
      proceeds from maturities of available-for-sale securities and held-to-maturity securities
    		                                      5,000,000                                          
      15
    		                                                                                
      net proceeds from share-based compensation
    		                                                                                
      earnings/(loss) from discontinued operations, net of tax
    		                                                                                
      net proceeds from issuance of common shares
    		                                        13,000,000 24,000,000 10,000,000 25,000,000 8,000,000 80,000,000   58,000,000                                
      tax proceeds/(disbursements) from share-based compensation
    		                                            3,000,000 -3,000,000                                   
      table of contents
    		                                                                                
      notes to condensed consolidated financial statements
    		                                                                                
      income from discontinued operations, net of tax
    		                                               1,000,000 0   1,000,000                             
      decrease in inventories
    		                                           199,000,000                            232,500,000   66,300,000 117,800,000     
      decrease in accounts payable
    		                                           -157,000,000                            -63,200,000         
      (earnings)/income from discontinued operations, net of tax
    		                                            0                                    
      gain on sale of investments
    		                                            0                                    
      purchase of available-for-sale securities, held-to-maturity securities and other investments
    		                                                                                
      proceeds from maturities of held-to-maturity securities
    		                                                0 0 48,000,000 23,000,000 46,000,000 11,000,000 25,000,000 10,000,000                         
      notes to consolidated financial statements
    		                                                                                
      proceeds from sale of other investments
    		                                                                                
      proceeds from issuance of common shares
    		                                               102,000,000   5,000,000 21,000,000 19,100,000 11,900,000 -7,100,000 18,100,000   2,500,000 8,400,000 15,500,000 -3,400,000 9,200,000 18,700,000 600,000 18,000,000 2,800,000 17,900,000 18,700,000 44,800,000 58,900,000 105,500,000 233,800,000 243,500,000 18,000,000 57,300,000 13,300,000 159,000,000 33,700,000 34,800,000 
      net tax disbursements from share-based compensation
    		                                               -15,000,000                                 
      gain on sale of investment in carefusion
    		                                                     0 0 0 -3,800,000 3,300,000 0 -74,800,000                     
      purchase of held-to-maturity securities and other investments
    		                                                    -24,500,000 0                           
      proceeds from sale of property and equipment
    		                                                         100,000 2,700,000 100,000  1,500,000 -500,000 4,800,000 900,000 300,000   22,300,000 2,900,000 4,900,000 2,500,000 5,500,000 -9,600,000 9,500,000 3,800,000 6,400,000 3,600,000 7,100,000 500,000 
      proceeds from sale of carefusion common stock
    		                                                       0     0 135,700,000                   
      tax disbursements from share-based compensation
    		                                                  10,000,000 -22,000,000    -21,600,000    -14,100,000                     
      adjustments to reconcile earnings from continuing operations to net cash from operations:
    		                                                                                
      (earnings)/income from discontinued operations
    		                                                      2,300,000 300,000                         
      net cash from operating activities—continuing operations
    		                                                    -106,900,000 893,200,000 -114,500,000 504,200,000 119,800,000 914,200,000 143,400,000 217,700,000                     
      net cash from operating activities—discontinued operations
    		                                                     0 0 0                         
      proceeds from divestitures and sale of property and equipment
    		                                                                                
      net cash provided by/(used in) investing activities—continuing operations
    		                                                        -100,200,000 -74,400,000 -1,937,500,000 84,100,000                     
      net cash from investing activities—discontinued operations
    		                                                      0 0 0 0 0 0                     
      payment of contingent consideration
    		                                                                                
      payment of premiums for debt extinguishment
    		                                                        0 0 0 0   0 -66,400,000                 
      tax disbursements from exercises of stock options
    		                                                        -5,000,000 -5,800,000                       
      net cash from financing activities—continuing operations
    		                                                       -381,300,000 -52,100,000   -344,200,000                     
      net cash from financing activities—discontinued operations
    		                                                      0 0  0 0 0                     
      cash and equivalents at beginning of year
    		                                                                                
      cash and equivalents at end of year
    		                                                                                
      non-cash investing and financing transactions for:
    		                                                                                
      retained investment in carefusion at date of spin-off
    		                                                        0 0 0 0                     
      non-cash dividend in connection with spin-off
    		                                                        0 0 0 0 -68,600,000 29,600,000 0 3,728,400,000                 
      cvs caremark corporation
    		                                                                                
      walgreen co.
    		                                                                                
      income from discontinued operations
    		                                                                 600,000 2,400,000 700,000    1,400,000    29,600,000 17,800,000    
      proceeds from sale of investment in carefusion
    		                                                     0    0 0 705,900,000                     
      tax proceeds/(disbursements) from exercises of stock options
    		                                                     3,300,000      2,000,000                     
      employee related costs
    		                                                     5,500,000 -1,300,000 2,700,000       -25,000,000 27,100,000                 
      facility exit and other costs
    		                                                     -100,000 -400,000 700,000       -24,000,000 32,600,000                 
      total restructuring and employee severance
    		                                                     5,400,000 -1,700,000 3,400,000       -49,000,000 59,700,000                 
      impairments and loss on sale of assets
    		                                                      1,100,000 1,300,000 400,000 4,600,000 1,700,000 1,900,000  4,200,000 400,000 23,600,000                 
      net cash from investing activities—continuing operations
    		                                                                                
      net cash provided by/(used in) financing activities—continuing operations
    		                                                                                
      net cash from /(used in) investing activities—continuing operations
    		                                                       -41,600,000                         
      excess tax benefit from exercises of stock options
    		                                                       4,900,000                         
      net cash provided by/(used in) operating activities—discontinued operations
    		                                                        0 -200,000 400,000 -700,000                     
      purchase of held-to-maturity investment securities
    		                                                        0 -14,600,000                       
      net cash provided by/(used in) financing activities—discontinued operations
    		                                                                                
      cash payments for:
    		                                                                                
      interest
    		                                                                                
      income taxes
    		                                                                                
      1.
    		                                                                                
      (earnings)/ income from discontinued operations
    		                                                                                
      acquisition of subsidiaries, net of divestitures and cash acquired
    		                                                              0 -32,000,000   -100,000 -6,100,000 -475,900,000 200,000 48,900,000 -88,100,000 -1,480,800,000 -28,000,000 -76,600,000 -44,400,000 -256,600,000 -33,100,000   
      issuance of common shares
    		                                                                                
      earnings from discontinued operations
    		                                                          -500,000 -400,000   -4,300,000 -23,600,000                 
      earnings/(loss) from continuing operations
    		                                                           294,400,000    -61,800,000                 
      adjustments to reconcile earnings/(loss) from continuing operations to net cash from operations:
    		                                                                                
      gain on sale of carefusion common stock
    		                                                                                
      impairments and (gain)/loss on sale of assets
    		                                                                                
      proceeds from divestitures
    		                                                                                
      net additions to property and equipment
    		                                                                   -88,600,000             
      sale of investment securities available for sale
    		                                                                     0 0 131,900,000         
      share-based payment compensation
    		                                                                                
      net cash from operating activities – continuing operations
    		                                                                     897,200,000 -24,100,000 439,200,000  685,800,000 -113,300,000 722,100,000     
      net cash from operating activities – discontinued operations
    		                                                             1,100,000 2,400,000 144,400,000  -700,000 -2,300,000 -900,000      84,600,000 34,400,000 -3,800,000     
      net cash provided by/(used in) investing activities – continuing operations
    		                                                             88,100,000                   
      net cash from investing activities – discontinued operations
    		                                                              0 -9,900,000          -72,200,000       
      tax expense from stock options
    		                                                                                
      net cash from financing activities – continuing operations
    		                                                              -454,200,000 -1,252,500,000  -134,600,000 -89,800,000 -171,500,000  -466,200,000 -52,200,000 -382,800,000         
      net cash provided by/(used in) financing activities – discontinued operations
    		                                                             0 0 1,283,800,000                 
      supplemental information
    		                                                                                
      investment in carefusion
    		                                                             0 2,300,000 860,800,000                 
      share based payment compensation
    		                                                                                
      net cash provided by/(used in) operating activities – continuing operations
    		                                                              522,200,000 261,600,000                 
      net change in commercial paper and short-term borrowings
    		                                                                 -100,100,000 99,900,000 1,200,000 -202,700,000 -317,200,000 287,400,000 232,000,000 -293,400,000 250,800,000 -97,700,000 101,400,000 -30,900,000 -1,700,000 3,000,000 3,000,000 
      tax (expense)/benefit from stock options
    		                                                                                
      loss on debt extinguishment
    		                                                               39,900,000                 
      equity compensation
    		                                                               22,000,000 30,500,000 33,100,000 34,800,000 24,400,000 35,600,000 32,200,000 28,400,000 26,100,000 28,800,000 38,900,000 25,400,000 45,000,000 52,100,000 46,500,000 55,800,000 82,900,000 
      net cash from investing activities – continuing operations
    		                                                               -64,200,000  -92,900,000 -81,400,000 -94,700,000  -76,400,000 -26,800,000 -45,200,000  40,400,000 -146,400,000 -84,000,000     
      tax benefit/(expense) from stock options
    		                                                               -6,200,000                 
      asset impairments and (gain)/loss on sale of assets
    		                                                                11,500,000                
      acquired in-process research and development
    		                                                                                
      increase in net investment in sales-type leases
    		                                                                8,100,000 -1,300,000 -14,800,000 -20,200,000 -41,100,000 -25,200,000 -34,500,000 -24,100,000 -53,800,000 -32,700,000 -23,400,000 -20,900,000 -31,000,000 -20,200,000 -23,100,000 -38,800,000 
      net cash provided by/(used in) investing activities—discontinued operations
    		                                                                                
      tax benefit/(expense) from exercises of stock options
    		                                                                                
      (increase) / decrease in inventories
    		                                                                                
      increase / (decrease) in accounts payable
    		                                                                 340,000,000    -37,300,000           
      acquisition of businesses, net of divestitures and cash acquired
    		                                                                                
      tax benefit / (expense) from stock options
    		                                                                                
      purchase of common shares in treasury
    		                                                                                
      net cash from financing activities – discontinued operations
    		                                                                           -17,800,000     
      •
    		                                                                                
      impairments, (gain) / loss on sale of assets and other
    		                                                                                
      net cash from / (used in) operating activities – continuing operations
    		                                                                  273,900,000 -352,000,000             
      net cash from / (used in) operating activities
    		                                                                  271,600,000 -352,900,000             
      tax benefits from exercises of stock options
    		                                                                  -1,000,000 3,300,000 26,800,000 1,300,000 2,400,000 11,600,000 1,200,000 11,600,000 3,100,000 14,000,000 6,300,000 21,400,000   
      restructuring charges
    		                                                                  -35,500,000 49,700,000  -23,000,000 16,700,000 14,800,000         
      acquisition integration charges
    		                                                                  3,400,000 2,400,000  -5,600,000 4,600,000 5,400,000         
      litigation
    		                                                                  -500,000 300,000             
      other
    		                                                                     100,000 -500,000 1,500,000         
      total special items
    		                                                                  -32,700,000 52,400,000  6,100,000 7,000,000 22,500,000         
      tax effect of special items
    		                                                                  9,900,000 -17,100,000  -1,700,000 -3,500,000 -7,700,000         
      decrease in net earnings from special items
    		                                                                                
      decrease in diluted earnings per common share from special items
    		                                                                                
      adjustments to reconcile earnings from continuing operations to net cash from / (used in) operating activities:
    		                                                                                
      asset impairments and (gain) / loss on sale of assets
    		                                                                   3,600,000             
      net earnings effect of special items
    		                                                                   35,300,000  4,400,000 3,500,000 14,800,000         
      net decrease in diluted earnings per common share
    		                                                                   100,000             
      (decrease)/increase in accounts payable
    		                                                                                
      sale/(purchase) of investment securities available for sale
    		                                                                         167,100,000 -10,600,000 41,900,000     
      (earnings) / income from discontinued operations
    		                                                                     9,900,000           
      asset impairments and other
    		                                                                     2,400,000           
      net cash from / (used in) operating activities – discontinued operations
    		                                                                     -10,000,000           
      purchase common shares in treasury
    		                                                                                
      net decrease in diluted earnings per share
    		                                                                                
      increase in other accrued liabilities and operating items
    		                                                                                
      litigation settlements
    		                                                                      -13,800,000 800,000         
      net decrease in diluted eps
    		                                                                      10,000 40,000         
      asset impairments
    		                                                                       -200,000 1,200,000 3,600,000 10,800,000 3,600,000 1,900,000 16,700,000 3,000,000 2,500,000 
      (increase) / decrease in trade receivables
    		                                                                       -191,900,000         
      net cash (used in) / provided by operating activities – discontinued operations
    		                                                                       -30,400,000         
      net (decrease) / increase in cash and equivalents
    		                                                                       -19,200,000         
      net cash from operating activities — continuing operations
    		                                                                                
      net cash from operating activities — discontinued operations
    		                                                                                
      sale (purchase) of investment securities available for sale
    		                                                                                
      net cash from investing activities — continuing operations
    		                                                                                
      net cash provided by/(used in) investing activities — discontinued operations
    		                                                                                
      net cash from financing activities — continuing operations
    		                                                                                
      net cash from financing activities — discontinued operations
    		                                                                                
      decrease / (increase) in inventories
    		                                                                                
      net cash (used in) / provided by financing activities – discontinued operations
    		                                                                                
      net (decrease)/increase in cash and equivalents
    		                                                                         -137,800,000       
      weighted-average common shares – basic
    		                                                                         -7,600,000 -2,300,000 404,500,000  -6,400,000 -800,000 426,300,000 
      effect of dilutive securities:
    		                                                                                
      employee stock options and unvested restricted shares and share units
    		                                                                          -100,000 8,500,000     
      weighted-average common shares – diluted
    		                                                                         -16,000,000 -2,400,000 413,000,000  -4,400,000 500,000 431,400,000 
      net cash (used in)/provided by financing activities – continuing operations
    		                                                                                
      net cash (used in)/provided by financing activities – discontinued operations
    		                                                                                
      net cash (used in)/provided by financing activities
    		                                                                                
      net cash provided by/(used in) investing activities – discontinued operations
    		                                                                           100,000     
      net cash provided by/(used in) financing activities – continuing operations
    		                                                                           -327,900,000     
      cumulative effect of change in accounting
    		                                                                                
      earnings from continuing operations before cumulative effect of change in accounting
    		                                                                                
      adjustments to reconcile earnings from continuing operations before cumulative effect of change in accounting to net cash from operations:
    		                                                                                
      net cash from operating activities - continuing operations
    		                                                                                
      net cash (used in) / provided by operating activities - discontinued operations
    		                                                                                
      purchase of investment securities available for sale
    		                                                                            800,000 -80,200,000 -219,200,000 -100,000,000 
      net cash from investing activities - continuing operations
    		                                                                                
      net cash (used in) / provided by investing activities - discontinued operations
    		                                                                                
      net cash from financing activities - continuing operations
    		                                                                                
      net cash from / (used in) financing activities - discontinued operations
    		                                                                                
      net cash (used in)/provided by operating activities – discontinued operations
    		                                                                                
      net cash (used in)/provided by investing activities – discontinued operations
    		                                                                                
      employee options and unvested restricted shares and share units
    		                                                                                
      proceeds from sale of discontinued operations
    		                                                                                
      divestiture/(acquisition) of subsidiaries, net of cash acquired
    		                                                                               3,300,000 
      tax benefits from exercises of stock options and other
    		                                                                               9,400,000 
      employee stock options, unvested restricted shares and share units
    		                                                                               5,100,000 
    The information provided in this report is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.